Do analysts recommend FBRX or ORMP?

Forte Biosciences currently has a consensus price target of $68.75, indicating a potential upside of 25.50%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forte Biosciences 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, FBRX or ORMP?

Forte Biosciences is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.64 N/A Oramed Pharmaceuticals N/A N/A $64.05M $2.59 1.56

Is FBRX or ORMP more profitable?

Oramed Pharmaceuticals' return on equity of -5.37% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -106.17% -85.50% Oramed Pharmaceuticals N/A -5.37% -4.83%

Do analysts rate ORMP or GYRE?

Gyre Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 186.20%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Gyre Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts recommend ORMP or ALLO?

Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 389.78%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Allogene Therapeutics 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.69

Which has stronger valuation and earnings, ORMP or ALLO?

Allogene Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oramed Pharmaceuticals N/A N/A $64.05M $2.59 1.56 Allogene Therapeutics N/A N/A -$190.89M -$0.77 N/A

Is ORMP or ALLO more profitable?

Oramed Pharmaceuticals' return on equity of -5.37% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.37% -4.83% Allogene Therapeutics N/A -56.45% -40.36%

Do analysts prefer ORMP or CRMD?

CorMedix has a consensus price target of $14.86, suggesting a potential upside of 88.78%. Given CorMedix's stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 CorMedix 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75

Oramed Pharmaceuticals (ORMP) Competitors

$4.03 -0.13 (-3.13%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$4.03 0.00 (-0.12%)

As of 07/24/2026 07:34 PM Eastern

Compare

ORMP vs. FBRX, GYRE, SPRY, ALLO, and CRMD

Should you buy Oramed Pharmaceuticals stock or one of its competitors? MarketBeat compares Oramed Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oramed Pharmaceuticals include Forte Biosciences (FBRX), Gyre Therapeutics (GYRE), ARS Pharmaceuticals (SPRY), Allogene Therapeutics (ALLO), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry.

How does Oramed Pharmaceuticals compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

In the previous week, Forte Biosciences had 10 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 11 mentions for Forte Biosciences and 1 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.89 beat Forte Biosciences' score of 0.63 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Forte Biosciences	Positive
Oramed Pharmaceuticals	Very Positive

Forte Biosciences has a beta of 2.85, indicating that its stock price is 185% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

Oramed Pharmaceuticals' return on equity of -5.37% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

Forte Biosciences currently has a consensus price target of $68.75, indicating a potential upside of 25.50%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Forte Biosciences is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$2.59	1.56

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Oramed Pharmaceuticals beats Forte Biosciences on 7 of the 13 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Gyre Therapeutics?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Oramed Pharmaceuticals has higher earnings, but lower revenue than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$2.59	1.56
Gyre Therapeutics	$116.59M	5.68	$5.03M	-$0.09	N/A

Oramed Pharmaceuticals has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market.

In the previous week, Oramed Pharmaceuticals and Oramed Pharmaceuticals both had 1 articles in the media. Oramed Pharmaceuticals' average media sentiment score of 1.89 beat Gyre Therapeutics' score of 1.87 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Oramed Pharmaceuticals	Very Positive
Gyre Therapeutics	Very Positive

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oramed Pharmaceuticals has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Oramed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Gyre Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 186.20%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Gyre Therapeutics beats Oramed Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, ARS Pharmaceuticals had 6 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 7 mentions for ARS Pharmaceuticals and 1 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.89 beat ARS Pharmaceuticals' score of 0.54 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ARS Pharmaceuticals	Positive
Oramed Pharmaceuticals	Very Positive

ARS Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Oramed Pharmaceuticals has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Oramed Pharmaceuticals' return on equity of -5.37% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

ARS Pharmaceuticals currently has a consensus target price of $28.20, indicating a potential upside of 374.75%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe ARS Pharmaceuticals is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oramed Pharmaceuticals has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	7.00	-$171.30M	-$2.01	N/A
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$2.59	1.56

Summary

Oramed Pharmaceuticals beats ARS Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Allogene Therapeutics?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 389.78%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, Allogene Therapeutics had 1 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 2 mentions for Allogene Therapeutics and 1 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.89 beat Allogene Therapeutics' score of 1.56 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Oramed Pharmaceuticals	Very Positive
Allogene Therapeutics	Very Positive

Allogene Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$2.59	1.56
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A

Oramed Pharmaceuticals' return on equity of -5.37% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%
Allogene Therapeutics	N/A	-56.45%	-40.36%

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Oramed Pharmaceuticals has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

Summary

Oramed Pharmaceuticals beats Allogene Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to CorMedix?

Oramed Pharmaceuticals (NASDAQ:ORMP) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, CorMedix had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 3 mentions for CorMedix and 1 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.89 beat CorMedix's score of 1.07 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Oramed Pharmaceuticals	Very Positive
CorMedix	Positive

Oramed Pharmaceuticals has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

CorMedix has a consensus price target of $14.86, suggesting a potential upside of 88.78%. Given CorMedix's stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

CorMedix has a net margin of 45.25% compared to Oramed Pharmaceuticals' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Oramed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%
CorMedix	45.25%	45.57%	24.76%

CorMedix has higher revenue and earnings than Oramed Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$2.59	1.56
CorMedix	$311.71M	1.98	$163.05M	$2.13	3.69

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

CorMedix beats Oramed Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Get Oramed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORMP vs. The Competition

Export

Metric	Oramed Pharmaceuticals	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$170.25M	$8.68B	$6.88B	$12.25B
Dividend Yield	6.22%	2.52%	2.67%	9.79%
P/E Ratio	1.56	18.51	27.00	23.71
Price / Sales	N/A	7.24	492.66	73.79
Price / Cash	45.85	18.17	50.54	59.64
Price / Book	0.80	3.19	10.28	6.07
Net Income	$64.05M	$230.22M	$3.60B	$331.84M
7 Day Performance	N/A	21.69%	-1.25%	-1.53%
1 Month Performance	-19.40%	20.21%	-0.35%	-2.46%
1 Year Performance	86.57%	-4.57%	18.41%	13.66%

Oramed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORMP Oramed Pharmaceuticals	3.0093 of 5 stars	$4.03 -3.1%	N/A	+79.9%	$170.25M	N/A	1.56	10	Positive News
FBRX Forte Biosciences	2.3834 of 5 stars	$50.73 +6.8%	$68.75 +35.5%	+409.6%	$659.43M	N/A	N/A	5	News Coverage Analyst Forecast
GYRE Gyre Therapeutics	2.4837 of 5 stars	$6.06 +3.1%	$17.00 +180.5%	-19.5%	$655.55M	$116.59M	N/A	40	Positive News
SPRY ARS Pharmaceuticals	2.2935 of 5 stars	$6.36 -1.2%	$28.20 +343.4%	-66.9%	$639.51M	$84.28M	N/A	90	High Trading Volume
ALLO Allogene Therapeutics	2.6205 of 5 stars	$1.85 +4.5%	$8.52 +360.7%	+15.2%	$610.92M	N/A	N/A	310	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORMP) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. FBRX, GYRE, SPRY, ALLO, and CRMD

How does Oramed Pharmaceuticals compare to Forte Biosciences?

Summary

How does Oramed Pharmaceuticals compare to Gyre Therapeutics?

Summary

How does Oramed Pharmaceuticals compare to ARS Pharmaceuticals?

Summary

How does Oramed Pharmaceuticals compare to Allogene Therapeutics?

Summary

How does Oramed Pharmaceuticals compare to CorMedix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. FBRX, GYRE, SPRY, ALLO, and CRMD

How does Oramed Pharmaceuticals compare to Forte Biosciences?

Does the media favor FBRX or ORMP?

Which has more risk & volatility, FBRX or ORMP?

Is FBRX or ORMP more profitable?

Do analysts recommend FBRX or ORMP?

Which has higher valuation & earnings, FBRX or ORMP?

Do insiders & institutionals believe in FBRX or ORMP?

Summary

How does Oramed Pharmaceuticals compare to Gyre Therapeutics?

Which has better earnings and valuation, ORMP or GYRE?

Which has more risk & volatility, ORMP or GYRE?

Does the media refer more to ORMP or GYRE?

Do institutionals & insiders have more ownership in ORMP or GYRE?

Is ORMP or GYRE more profitable?

Do analysts rate ORMP or GYRE?

Summary

How does Oramed Pharmaceuticals compare to ARS Pharmaceuticals?

Does the media favor SPRY or ORMP?

Which has more volatility and risk, SPRY or ORMP?

Is SPRY or ORMP more profitable?

Do analysts rate SPRY or ORMP?

Do insiders and institutionals believe in SPRY or ORMP?

Which has higher valuation and earnings, SPRY or ORMP?

Summary

How does Oramed Pharmaceuticals compare to Allogene Therapeutics?

Do analysts recommend ORMP or ALLO?

Does the media favor ORMP or ALLO?

Which has stronger valuation and earnings, ORMP or ALLO?

Is ORMP or ALLO more profitable?

Do institutionals and insiders hold more shares of ORMP or ALLO?

Which has more volatility & risk, ORMP or ALLO?

Summary

How does Oramed Pharmaceuticals compare to CorMedix?

Does the media favor ORMP or CRMD?

Which has more risk & volatility, ORMP or CRMD?

Do analysts prefer ORMP or CRMD?

Is ORMP or CRMD more profitable?

Which has stronger earnings & valuation, ORMP or CRMD?

Do institutionals and insiders have more ownership in ORMP or CRMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools